ERBB2 and breast carcinoma: When co-cultured with human PBMC, trastuzumab, the anti-human epidermal growth factor receptor-2 (HER2) antibody, is shown to upregulate PD-L1 in HER2-overexpressing breast cancer cells via mediating stimulation of IFN-γ secretion on immune cells [29].